$599

Lilly/Hims Official Partnership; Tandem and MannKind Q3 ’26 Earnings; MetaVia Ph1 OXM Analog Data

A series of cardiometabolic-related news items has been observed from Lilly, Tandem, MannKind, and MetaVia. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here